Vector-borne diseases (VBDs) are a significant public health concern in India, posing a complex challenge to the healthcare system. They account for more than 17% of all infectious diseases, causing substantial morbidity and mortality. This article provides an in-depth analysis of the rising VBDs in India and the strategies to combat them.
India's diverse climatic conditions and high population density create an ideal breeding ground for vectors such as mosquitoes, ticks, and flies, leading to the spread of diseases like malaria, dengue, and chikungunya. The burden of these diseases is on the rise, with dengue cases increasing five-fold over the last decade.
Several factors contribute to the difficulty in controlling VBDs in India, including inadequate surveillance, insufficient public health infrastructure, and socio-economic disparities. Additionally, climate change and urbanization are exacerbating the spread of vectors, further complicating control efforts.
India's National Vector Borne Disease Control Programme (NVBDCP) is the central initiative for controlling VBDs. It focuses on early diagnosis and prompt treatment, integrated vector management, and public awareness. However, there is a need for more robust surveillance systems, improved diagnostic tools, and novel vector control strategies to enhance the effectiveness of the programme.
Healthcare professionals play a critical role in combating VBDs through patient education, early detection, and appropriate treatment. They are also instrumental in conducting research to understand disease patterns and developing innovative strategies for vector control.
While the burden of VBDs is increasing in India, concerted efforts from healthcare professionals, policymakers, and the community can turn the tide. Strengthening the existing strategies, investing in research and development, and fostering collaborations can significantly improve the control of vector-borne diseases in India's healthcare landscape.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation